Charter Life Sciences





	APT Pharmaceuticals Secures $32 Million in Series B Financing September 30, 2008 XLumena Spots $6M For Ultrasound Devices June 4, 2008 Mirabilis Completes First Human Trial of Non-Invasive Treatment for Uterine Fibroids APRIL 28, 2008 Astellas and CoMentis Sign Agreement to Collaborate on the Research, Development and Commercialization of Beta-Secretase Inhibitors APRIL 25, 2008 EnteroMedics Announces Planned Expansion of EMPOWER Pivotal Study for Obesity to 300 Patients February 26, 2008 KFx Medical Corporation Appoints Matt Meyer as its Vice President Marketing February 20, 2008 EnteroMedics(TM) Announces Nine-Month Clinical Results on Its VBLOC-RF2 Feasibility Study for Obesity Therapy January 8, 2008 EnteroMedics(TM) Announces Pivotal Clinical Study of its VBLOC(TM) Therapy for Obesity January 7, 2008 CoMentis Announces Proof-of-Activity-Data from its Phase I Study of Disease-Modifying Alzheimer’s Disease Therapy January 7, 2008 APT Pharmaceuticals Expands Management Team NOVEMBER 19, 2007 EnteroMedics Announces Initial Public Offering NOVEMBER 14, 2007 APT Pharmaceuticals Closes New $22 Million Funding Round OCTOBER 4, 2007 JDRF Partners with CoMentis for Diabetic Macular Edema Clinical Trial SEPTEMBER 20, 2007 Mirabilis Closes $10.5 Million Series A Extension to Commercialize Non-invasive Treatment of Uterine Fibroids AUGUST 21, 2007 KFx Medical Corporation Closes $10 Million Series B Financing AUGUST 9, 2007 JDRF Partners with CoMentis for Diabetic Macular Edema Clinical Trial JUNE 18, 2007 CoMentis Announces Appointment of Martin Tolar, M.D., Ph.D., as Vice President JUNE 6, 2007 APT Acquires Exclusive Worldwide Rights to Develop and Commercialize Inhalable Cyclosporine to Prevent Lung Transplant Rejection JUNE 5, 2007 Enteromedics Files Registration Statement for Proposed Initial Public Offering MAY 25, 2007 CoMentis Initiates Phase II Clinical Trial for AMD Eye Drop Therapy APRIL 10, 2007 Athenagen Announces Name Change to CoMentis FEBRUARY 10, 2007 Athenagen’s Eye Drop Therapy for AMD is Safe and Well Tolerated in Phase I Study JANUARY 31, 2007 Athenagen Initiates Phase II Clinical Trial in Alzheimer’s Disease DECEMBER 13, 2006 Mirabilis Medica Names Mike Connolly CEO OCTOBER 3, 2006 Athenagen Raises $50 Million in Series B Financing SEPTEMBER 28, 2006 Amaranth Medical Closes $7.5 Million Series A Financing to Advance the Development of Bio-Absorbable Stents SEPTEMBER 26, 2006 Mirabilis Raises $4 Million to Commercialize Non-Invasive Treatment of Uterine Fibroids AUGUST 29, 2006 Athenagen Initiates Clinical Development of its Anti-angiogenic Eye Drop Therapy for AMD AUGUST 21, 2006 Athenagen Completes Merger with Zapaq AUGUST 14, 2006 KFx Medical Corporation Receives 510k Clearance for Knotless Tissue Fixation AUGUST 10, 2006 Athenagen Announces Publication of Results from a Proof-of-Concept Trial of its Novel alpha-7 Nicontinic Receptor Agonist in Schizophrenia JUNE 15, 2006 Athenagen Acquires Osprey Pharmaceutical Company - Adds Clinical-Stage Alzheimer's Drug Candidate to its Pipeline APRIL 13, 2006 Aradigm and APT Pharmaceuticals Initiate Phase 2 Clinical Program of Novel Treatment for Asthma MARCH 23, 2006 Athenagen Adds A. Barr Dolan to its Board of Directors FEBRUARY 22, 2006 Previous News Stories >


	About CLS
	CHARTER LIFE SCIENCES (“CLS”) is a clinical stage life sciences venture capital investor. CLS makes initial portfolio company investments in life sciences companies that are seeking capital to obtain initial clinical proof-of-efficacy of their products (see Investment Criteria), and we continue to support our successful portfolio companies with follow on investments until they are acquired or go public. Our team is led by four Managing Partners who have worked together to create and build life sciences companies for over twenty years. We take a team approach to all of our investments, and our team brings extensive scientific, clinical, regulatory, operational and finance experience to each of our portfolio companies. We play an active role in helping entrepreneurs build successful companies. Our time, energy and passion is devoted to investing in early stage life sciences opportunities. As a result, your company will be compared only against other early stage opportunities. So, at CLS, your preclinical biotech or medical device company will not be compared against a PIPE investment in an undervalued Phase III company. Early stage is what we do, and all we do. We understand that early stage companies do not have all the answers and do not have all the data. We understand that many basic questions need investment capital to answer, and we understand that development plans and milestones are subject to lots of uncertainty and change. We understand what it takes to build a management team from scratch, and we invest in companies with little or no existing management. In short, we understand what it is to be an early stage entrepreneur, because each of us has been one. Please look carefully at our investment criteria and our team, and if we are the type of partner that you would like to work with, please contact us.